WILMINGTON, DE — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) will release its second-quarter 2025 financial results after market close on Thursday, August 14, followed by a 4:30 p.m. ET conference call to discuss recent regulatory developments, strategic plans, and operational priorities.
The clinical-stage biopharmaceutical company is advancing therapies from its NMDA platform for conditions including suicidal depression, chronic pain, and PTSD. Its lead candidates, NRX-100 (IV ketamine) and NRX-101 (oral D-cycloserine/lurasidone), have both received expedited FDA designations, with an NDA for NRX-101 planned under Accelerated Approval.
NRx has also filed an ANDA and begun the NDA process for NRX-100, supported by clinical trial data from U.S. and French government studies.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.